Possible role of the adrenergic mechanism in gastric inhibitory polypeptide-and glucagon-like peptide-1 (7–36) amide-induced insulin release in the rat

Gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1(7–36) amide (GLP-1) are thought to be the most probable candidates for incretin. However, the precise mechanism of incretin effect is unclear. In the present study, to elucidate the possible role of the autonomic nervous system in incr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Metabolism, clinical and experimental clinical and experimental, 1993-02, Vol.42 (2), p.209-213
Hauptverfasser: Ikeda, Tadasu, Ochi, Hiroshi, Ohtani, Izumi, Fujiyama, Katsumi, Hoshino, Tazue, Tanaka, Yasushi, Takeuchi, Tatsuo, Mashiba, Hiroto
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1(7–36) amide (GLP-1) are thought to be the most probable candidates for incretin. However, the precise mechanism of incretin effect is unclear. In the present study, to elucidate the possible role of the autonomic nervous system in incretin effect, the effects of atropine, propranolol, metoprolol, and phentolamine on GIP- or GLP-1-induced insulin release were investigated in the rat. The GIP-induced (2 or 20μg) insulin release was partly inhibited by propranolol pretreatment (0.5 mg/kg subcutaneously [SC]), and GLP-1-induced (2 or 20 μg) insulin release was partly inhibited by propranolol or metoprolol (35 mg/kg SC). These results suggest that a β-adrenergic mechanism may be involved in the incretin effect, probably through a modulating effect on GIP- or GLP-1-induced insulin secretion.
ISSN:0026-0495
1532-8600
DOI:10.1016/0026-0495(93)90037-O